The founders have collectively over 100 years of experience in neuroscience. Our collective experience and expertise in all the critical areas provides the leadership needed for successfully advancing new drugs into clinical trials.
Our scientific team has discovered and patent-protected ideal drug candidates with the following properties:
- Peptides that exhibit in vivo activity similar to large proteins
- Small molecule
- Ultra-low immunogenicity
- Specific action
- Easy to synthesize and modify
- Non-invasive delivery to CNS
Our approach uses non-invasive drug delivery to treat neurodegenerative diseases such as:
- Parkinson’s disease
- Alzheimer’s disease
- Huntington’s disease
- Brain aging processes
Our molecules distribute quickly throughout the brain and are taken up by target neurons.
The research and regulatory steps for taking a new drug candidates from the laboratory into clinical testing requires a strongly dedicated and experienced leadership team. Our collective expertise and experience, over 100+ years, provides the leadership needed for successfully advancing new drugs into clinical trials.
Raymond Bartus, PhD
Dr. Bartus was trained in Neuroscience and has a unique 35+ year track record of being a productive researcher as well as a successful 'translational scientist'. He conceived, discovered and/or developed multiple therapeutics for human diseases (17 products advanced into clinical trials, seven approved for marketing). Dr. Bartus is a Full Partner and team leader for drug development and regulatory filings.
Luke Bradley, PhD
Dr. Bradley received training in Peptide and Protein Chemistry, working on designing, synthesizing, characterizing and screening large collections of novel/synthetic candidate biomolecules rich in novel binding and enzymatic activities. He has applied this technology towards drug discovery for the treatment of neurological disorders. Dr. Bradley is a Founding Partner and CEO.
Don M. Gash, PhD
Dr. Gash received his training in Neurobiology and Anatomy. He has 35+ years of experience in developing new therapies for age-associated diseases and dysfunctions. He established the Good Laboratory Practice (GLP) Neuroscience Center with colleagues at the University of Kentucky for conducting FDA Compliant preclinical enabling studies. Dr. Gash is a Founding Partner.
Greg Gerhardt, PhD
Dr. Gerhardt received training in Analytical Chemistry/Neuroscience. He has 35+ years of experience in "bench-to-bedside" development of novel therapeutics and therapies for neurodegenerative diseases and psychiatric disorders. He is currently the Co-Director of the Brain Restoration Center and Directory of the Good Laboratory Practice (GLP) Center at the University of Kentucky. Dr. Gerhardt is a Founding Partner.